Actym is harnessing the power of a genetically modified bacterial vehicle that can safely introduce different combinations of therapeutic payloads into the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered cancer treatment that exploits TME-specific metabolites critical for bacterial enrichment. With our approach, we aim to activate the immune response within the TME to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Press Release | June 25, 2024
Press Release | May 30, 2024
Actym Therapeutics is a dynamic, innovative, and fast growing company. Our people are our greatest asset. Come join us! We are always looking for outstanding scientists who share our passion for scientific innovation and are guided by our core values.